PE20120218A1 - Compuestos para el tratamiento de trastornos metabolicos - Google Patents

Compuestos para el tratamiento de trastornos metabolicos

Info

Publication number
PE20120218A1
PE20120218A1 PE2011001638A PE2011001638A PE20120218A1 PE 20120218 A1 PE20120218 A1 PE 20120218A1 PE 2011001638 A PE2011001638 A PE 2011001638A PE 2011001638 A PE2011001638 A PE 2011001638A PE 20120218 A1 PE20120218 A1 PE 20120218A1
Authority
PE
Peru
Prior art keywords
piperidin
alkyl
compounds
halo
treatment
Prior art date
Application number
PE2011001638A
Other languages
English (en)
Inventor
Oscar Barba
Tom Banksia Dupree
Peter Timothy Fry
Matthew Colin Thor Fyfe
Revathy Perpetua Jeevaratnam
Thomas Martin Krulle
Karen Lesley Schofield
Donald Smyth
Thomas Staroske
Alan John William Stewart
David French Stonehouse
Simon Andrew Swain
David Matthew Withall
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of PE20120218A1 publication Critical patent/PE20120218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE Z ES C(O)OR4, HETEROARILO, ENTRE OTROS, EN DONDE R4 ES ALQUILO(C2-C6) O CICLOALQUILO(C3-C6); X ES O, NR7 O CR6R66, EN DONDE R6 Y R66 SON CADA UNO H, F O ALQUILO(C1-C4); R7 ES H O ALQUILO(C1-C4); Y ES ALQUILENO(C2-C4) OPCIONALMENTE SUSTITUIDO CON F O METILO; A ES FENILO O UN ANILLO HETEROAROMATICO DE 6 MIEMBROS QUE CONTIENE 1 A 2 ATOMOS DE N; R1 ES H, HALO, CN, ALQUILO(C1-C4) O HALOALQUILO(C1-C4); R2 ES FENILO SUSTITUIDO OPCIONALMENTE CON HALO, PIRIDILO SUSTITUIDO OPCIONALMENTE CON HALO O METILO, ENTRE OTROS; p ES 1 O 2; q ES 1 O 2. SON COMPUESTOS PREFERIDOS: 1-[(3S,4S)-4-AMINO-1-(5-{(R)-3-[1-(5-CLOROPIRIMIDIN-2-IL)PIPERIDIN-4-IL]BUTOXI}PIRIMIDIN-2-IL)PIRROLIDIN-3-IL]PIPERIDIN-2-ONA, 1-[(3S,4S)-4-AMINO-1-(6-{(R)-3-[1-(3-ISOPROPIL-[1,2,4]OXADIAZOL-5-IL)PIPERIDIN-4-IL]BUTOXI}PIRIMIDIN-4-IL)PIRROLIDIN-3-IL]PIPERIDIN-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR ACOPLADO A PROTEINA G 119 (GPR119) SIENDO UTILES EN EL TRATAMIENTO DE DIABETES TIPO II, OBESIDAD, SINDROME METABOLICO, HIPERLIPIDEMIA
PE2011001638A 2009-03-12 2010-03-12 Compuestos para el tratamiento de trastornos metabolicos PE20120218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0904285.4A GB0904285D0 (en) 2009-03-12 2009-03-12 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
PE20120218A1 true PE20120218A1 (es) 2012-03-19

Family

ID=40600947

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001638A PE20120218A1 (es) 2009-03-12 2010-03-12 Compuestos para el tratamiento de trastornos metabolicos

Country Status (18)

Country Link
US (1) US20120059014A1 (es)
EP (1) EP2406251A1 (es)
JP (1) JP2012520283A (es)
KR (1) KR20110133045A (es)
CN (1) CN102395578A (es)
AU (1) AU2010222672A1 (es)
BR (1) BRPI1009783A2 (es)
CA (1) CA2754791A1 (es)
CL (1) CL2011002182A1 (es)
EA (1) EA201190207A1 (es)
GB (1) GB0904285D0 (es)
IL (1) IL215050A0 (es)
MA (1) MA33241B1 (es)
MX (1) MX2011009493A (es)
PE (1) PE20120218A1 (es)
SG (1) SG174363A1 (es)
WO (1) WO2010103334A1 (es)
ZA (1) ZA201107449B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
TW201111361A (en) 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
RU2606131C2 (ru) 2011-05-13 2017-01-10 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
GB2497351A (en) * 2011-12-09 2013-06-12 Prosidion Ltd Compounds useful as GPR119 agonists
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2016131198A1 (en) * 2015-02-18 2016-08-25 Eli Lilly And Company Pyrazole compounds
IL261606B (en) * 2016-03-16 2022-09-01 Kura Oncology Inc Inhibitors of converted menin-mll and methods of use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
EP1112359A2 (en) 1998-09-01 2001-07-04 BASF Aktiengesellschaft Enhanced functional expression of g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
WO2005061489A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
BRPI0516407A (pt) 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20090203676A1 (en) 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20100063081A1 (en) 2005-06-30 2010-03-11 Stuart Edward Bradly CPCR Agonists
WO2007116229A1 (en) 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
EP2094683B1 (en) 2006-12-06 2011-10-12 GlaxoSmithKline LLC Bicyclic compounds and use as antidiabetics
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EP2114936A1 (en) 2007-01-04 2009-11-11 Prosidion Limited Piperidine gpcr agonists
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
JP2010514828A (ja) 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンｇｐｃｒアゴニスト
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US20100286112A1 (en) 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
CN101827958A (zh) 2007-10-18 2010-09-08 日矿金属株式会社 金属包覆的聚酰亚胺复合体、该复合体的制造方法以及电子电路板的制造方法
CN101621337B (zh) 2008-06-30 2013-08-07 华为技术有限公司 一种时延调节装置与方法
US20110269734A1 (en) 2008-07-10 2011-11-03 Prosidion Limited Piperidinyl gpcr agonists
US20110230507A1 (en) 2008-07-10 2011-09-22 Prosidion Limited Piperidine GPCR Agonists
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Also Published As

Publication number Publication date
CL2011002182A1 (es) 2012-03-30
GB0904285D0 (en) 2009-04-22
SG174363A1 (en) 2011-10-28
JP2012520283A (ja) 2012-09-06
CN102395578A (zh) 2012-03-28
MX2011009493A (es) 2011-10-11
MA33241B1 (fr) 2012-05-02
BRPI1009783A2 (pt) 2016-03-08
EP2406251A1 (en) 2012-01-18
US20120059014A1 (en) 2012-03-08
AU2010222672A1 (en) 2011-11-03
WO2010103334A1 (en) 2010-09-16
EA201190207A1 (ru) 2012-04-30
CA2754791A1 (en) 2010-09-16
IL215050A0 (en) 2011-11-30
KR20110133045A (ko) 2011-12-09
ZA201107449B (en) 2012-06-27

Similar Documents

Publication Publication Date Title
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20081659A1 (es) Agonistas de gpcr
PE20090449A1 (es) Agonistas de receptor acoplado a proteina g gpr119 de piridona
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
AR064736A1 (es) Agonistas de gpcr
PE20110329A1 (es) Agonistas del receptor acoplado a la proteina g piperidinilo
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20141375A1 (es) Activadores de glucoquinasa
PE20121045A1 (es) Agonista de gpr119
PE20091527A1 (es) Derivados de piridazinona
PE20090222A1 (es) Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
PE20121336A1 (es) Nuevos compuestos triciclicos
CL2008002159A1 (es) Compuestos derivados de n-(((1r, 4r)-4-aminociclohexil)metil) sulfonaminas sustituidas con heterociclos, antagonistas del receptor npy y5; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar anorexia y obesidad.
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
HN2010002772A (es) Compuestos organicos nuevo titulo de la invencion: derivados de 2-(3-piridil)-indol sustituido y composicionesfarmaceuticas de los mismos. (bajo el escrito 2013-000513 de fecha 27 de febrero de 2013) solicitado por esta oficina de registro
PE20120399A1 (es) Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119
PE20080676A1 (es) Derivados de indol como antagonistas del receptor de glucagon
PE20091324A1 (es) Compuestos espiro como antagonistas del receptor npy y5
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
UY32884A (es) 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas
PE20090772A1 (es) Derivados de bencimidazol
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης

Legal Events

Date Code Title Description
FA Abandonment or withdrawal